Pharmacokinetics of injection of iodine-131 labelling MEI-TUO-XI monoclonal antibody in human body.
- Author:
Yunchun LI
1
;
Tianzhi TAN
;
Tingshu MO
;
Wusheng LU
;
Houfu DENG
;
Xiaochuan YANG
;
Xiao LI
Author Information
1. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antibodies, Monoclonal;
administration & dosage;
pharmacokinetics;
Antibodies, Neoplasm;
immunology;
Drug Delivery Systems;
Female;
Hepatic Artery;
Humans;
Immunoglobulin Fab Fragments;
Injections, Intra-Arterial;
Iodine Radioisotopes;
administration & dosage;
pharmacokinetics;
Liver Neoplasms;
immunology;
radiotherapy;
Male;
Middle Aged;
Radioimmunotherapy;
Young Adult
- From:
Journal of Biomedical Engineering
2007;24(4):857-861
- CountryChina
- Language:Chinese
-
Abstract:
To study pharmacokinetics of injection of iodine-131 labelling MEI-TUO-XI monoclonal antibody (hepatoma monoclonal antibody HAb18 F(ab')2) in vivo. 24 cases of primary hepatocelluar carcinoma (PHC) were equally divided into the low dose group, middle dose group and high dose group. After the relevant injection was administrated into the hepatic artery of each case, intravenous blood and urine samples were separately collected at different time for determination of the radioactive count ratio (min(-1)). The proportion of 131I-HAb18 F(ab')2 in serum of each blood sample was determined, and the radioactive count ratio (min(-1)) of druggery for each blood sample was revised according to the proportion. The pharmacokinetic parameters were calculated using DAS ver 1.0 (Drug And Statistics for Windows) program. The component of urine radiomaterial was determined and the percentages of urine radioactivity in administration dosage were calculated. The catabolism of the injection with time accorded with dynamics two-compartment model. The catabolism product was mainly free-131I and was excreted via kidney; the urine radioactivity was 47.70%-51.16% of administration dosage during 120 h after administration of drug. Therefore, the pharmacokinetics of the injection can satisfy the clinical demands. The drug dose recommended for clinical use was 27.75 MBq of the injection for each kg of human body.
